166 related articles for article (PubMed ID: 16855786)
21. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
22. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
[TBL] [Abstract][Full Text] [Related]
23. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
Holland D; Hoppe-Seyler K; Schuller B; Lohrey C; Maroldt J; Dürst M; Hoppe-Seyler F
Cancer Res; 2008 Dec; 68(23):9964-72. PubMed ID: 19047178
[TBL] [Abstract][Full Text] [Related]
24. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
25. A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations.
Tiwari VK; Cope L; McGarvey KM; Ohm JE; Baylin SB
Genome Res; 2008 Jul; 18(7):1171-9. PubMed ID: 18502945
[TBL] [Abstract][Full Text] [Related]
26. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
27. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
28. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.
Ding L; Erdmann C; Chinnaiyan AM; Merajver SD; Kleer CG
Cancer Res; 2006 Apr; 66(8):4095-9. PubMed ID: 16618729
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
32. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
33. Developmental biology: two paths to silence merge.
Taghavi P; van Lohuizen M
Nature; 2006 Feb; 439(7078):794-5. PubMed ID: 16482140
[No Abstract] [Full Text] [Related]
34. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
35. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
Fang J; Zhang M; Li Q
Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
[TBL] [Abstract][Full Text] [Related]
36. The role of EZH2 in tumour progression.
Chang CJ; Hung MC
Br J Cancer; 2012 Jan; 106(2):243-7. PubMed ID: 22187039
[TBL] [Abstract][Full Text] [Related]
37. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of Polycomb gene expression in brain tumors.
Crea F; Hurt EM; Farrar WL
Mol Cancer; 2010 Sep; 9():265. PubMed ID: 20920292
[TBL] [Abstract][Full Text] [Related]
39. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
[TBL] [Abstract][Full Text] [Related]
40. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]